Navigation Links
Efficient and Reliable Linear,,, Amplification of cRNA

Gene Expression Profiling Using Microarray Kits from Roche Applied Science

The use of gene-expression profiling, a genomic application measuring mRNA transcript levels of many genes in parallel, has been growing rapidly over the last few years. Besides the actual microarrays and instrumentation for hybridization and imaging, target preparation is of major importance for reliability and sensitivity of expression-profiling experiments. Several different target preparation strategies have been recently developed that are mainly related to the amount of starting material available.


Benefits of the Roche Applied Science Microarray Kits

  • High yield and integrity of labeled cRNA

  • Representational amplification of small amounts of RNA for gene-expression analysis

  • Seamless workflow from cDNA synthesis to cRNA labeling

  • Fast and easy procedure

  • Incorporation of hapten- or fluorescence-labeled nucleotides

  • Only one labeled nucleotide needed

  • Compatible with spotted or in situ synthesized microarrays

Target Preparation Workflow
Especially in medical research applications, sample material is often limited and therefore target amplification is mandatory. Starting from a few micrograms of total RNA, linear amplification of cRNA utilizing T7 RNA polymerase for the preparation of the labeled target, first described by van Gelder and Eberwine [1], has become a standard procedure (Figure 1 a). This protocol consists of a first- and second-strand cDNA synthesis followed by cRNA in vitro transcription using T7 RNA polymerase. For first-strand cDNA synthesis an oligo(dT) primer linked to the T7 promoter sequence is used. In the next step, this T7 linker allows the linear amplification of the template and the simultaneous incorporation of labeled nucleotides with T7 RNA polymerase, generating singlestranded, labeled cRNA. The complete target-preparation workflow consists of multiple enzymatic steps determining the quality and integrity of the targets.

Experimental Validation

To validate the T7 RNA polymerase-based target synthesis procedure, the Roche Applied Science (RAS) Microarray RNA Target Synthesis Kit (T7) and the kit of a major Supplier (A) were tested on three different human acute myeloid leukemia (AML) research samples and one chronic lymphocytic leukemia (CLL) research sample (Figure 1b).

First, 5 g of total RNA was converted into double-stranded (ds) cDNA using the RAS Microarray cDNA Synthesis Kit (eight independent reactions). One group of ds cDNA samples was purified with the RAS Microarray Target Purification Kit, then amplified with T7 RNA polymerase and labeled with Biotin-UTP, using the RAS Microarray RNA Target Synthesis Kit (T7). The resulting labeled cRNA was purified with the RAS Microarray Target Purification Kit. The ds cDNA of the other sample group was purified according to the Supplier As protocol, followed by in vitro transcription and labeling with Biotin- UTP and Biotin-CTP using Supplier As kit. Purification of the labeled cRNA was carried out according to Supplier As recommendations. For all samples, 10 g labeled cRNA was hybridized to HG-U133A GeneChip Arrays. To estimate the performance of the T7 amplification, the yield of biotin-labeled cRNA and the hybridization results obtained from HG-U133A GeneChip Arrays were analyzed (Table 1).

Fast Procedure with High Efficiency

The yield of labeled cRNA is slightly lower for three out of four samples using the RAS Microarray Kits. However, both reaction volume (20 l vs. 40 l) and reaction time (2 hours vs. 4 hours) are reduced by half with the RAS Microarray RNA Target Synthesis Kit (T7) compared to the approach of Supplier A, indicating the higher efficiency and swifter procedure provided by the kit. In addition, the RAS Microarray Target Purification Kit simplifies the cDNA/cRNA purification steps of the Eberwine protocol.

The hybridization data obtained from the HG-U133A GeneChip Arrays show a higher number of present calls for the labeled cRNA that was generated with the RAS Microarray RNA Target Synthesis Kit (T7), signifying increased sensitivity. The kit protocol is economically optimized for the incorporation of only one labeled nucleotide (e.g., Biotin-UTP), and our results indicate that there is no further improvement of sensitivity by additional labeled nucleotides.

Furthermore, the 3′ 5′ ratio of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) displays a lower ratio for these targets, demonstrating the larger amount and integrity of full-length cRNA targets achieved when using the RAS Microarray RNA Target Synthesis Kit (T7) for linear amplification and labeling.

The use of the RAS Microarray Kits demonstrates a more efficient target preparation procedure that results in a greater integrity of labeled target cRNA.


'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Efficiently Insert Unique Restriction Sites into Plasmid Vectors
2. Efficient Cleavage of Fusion Proteins to Yield Native Amino Termini
3. Mammalian Expression Vector for Efficient Cloning of PCR Fragments
4. Efficient Transfection of Neurospora Crassa
5. Efficient Transfection of Neurospora Crassa
6. Efficient Recovery of Ultrapure Plasmid DNA
7. Efficient and Reliable PCR Setup Using Eppendorf MasterMix
8. Efficient DNA transfection of primary CNS neurons using TransMessenger Transfection Reagent
9. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
10. Cloning Based on Efficient Three-Fragment Assembly DNA Ligation
11. Efficient Delivery of siRNAs to Human Primary Cells: Electroporation vs. Chemical Transfection
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Efficient and Reliable Linear Amplification cRNA

(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... - Revised Code Demonstrates Strong Commitment to Ethical Information ... ... Pharmaceutical Companies -, ROCKLAND, Mass., July 10 ... will fully implement, the revised,and strengthened PhRMA Code on Interactions ...
... TRENTON, N.J., July 10 Archi-Tech Systems, ... reporting solutions,today announced DART(TM) PromoTrack, a new ... pharmaceutical marketing campaigns and,prescriber promotions. Archi-Tech has ... specific needs of pharmaceutical marketers, seamlessly,integrating disparate ...
... Mixed-Pedigree Pups Can Now Bark Up Family Tree with DNA Testing ... ... tree has never been easier with new cutting-edge DNA testing for mixed-pedigree ... specialty retailer., , , , ,Beginning Tuesday, July 15, PETCO customers will ...
Cached Biology Technology:EMD Serono to Adopt Revised and Strengthened PhRMA Code 2EMD Serono to Adopt Revised and Strengthened PhRMA Code 3EMD Serono to Adopt Revised and Strengthened PhRMA Code 4Pharmaceutical Marketing Done Right: Archi-Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management 2PETCO Adds Canine Heritage Breed Test to its Innovative Assortment 2PETCO Adds Canine Heritage Breed Test to its Innovative Assortment 3PETCO Adds Canine Heritage Breed Test to its Innovative Assortment 4
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ... endpoints to toxicology studies has evolved from short ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... and management have not affected all socioeconomic groups equally, as ... awareness and outcomes. This year, the American Association ... Science of Cancer Health Disparities in Racial/Ethnic Minorities and the ... Fla. Findings presented at this year,s meeting will ...
... 2010) -- A new optical imaging technique described in ... is published by the American Institute of Physics, holds ... performed to treat patients with a partially or completely ... heart. Angioplasty involves threading a slender, balloon-tipped ...
... These days people usually don,t die from a heart attack. ... patients eventually succumb to congestive heart failure, the most common ... now offer hope for achieving what the body can,t do: ... Washington have built a scaffold that supports the growth and ...
Cached Biology News:Optical imaging technique for angioplasty 2A strategy to fix a broken heart 2A strategy to fix a broken heart 3
Request Info...
... This reagent is formulated specifically for ... consistently high levels of activity for both ... storage at final dilution. This product ... stability providing the customer a longer shelf ...
... nonspecific binding is a problem in ... of immobilized NeutrAvidin products as superior ... is a modified avidin derivative that ... a biotin-binding protein with exceptionally low ...
... ALH 4000 workstation is the simplest, easiest-to-use ... introduce automated liquid handling capabilities,into their labs, ... to support routine applications on a separate ... walk-away automation even when you have ...
Biology Products: